{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T23:16:33Z","timestamp":1773098193171,"version":"3.50.1"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T00:00:00Z","timestamp":1694390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T00:00:00Z","timestamp":1694390400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The COVID-19 pandemic has had a devastating impact on the health and wellbeing of the global population. This paper presents the results of a longitudinal transcultural study that was begun at the peak of the pandemic (in April, 2020). An online survey was used to collect data from English-, Spanish-, and Portuguese-speaking participants. The survey collected information about sociodemographics, lifestyle activities, COVID-19-related circumstances, and drug use (with an emphasis on hallucinogenic drugs), as well as involving psychometric questionnaires. Users of hallucinogenic drugs had higher psychological well-being and lower scores on psychopathology scales, both at baseline and during follow-ups. This difference was larger when users were distinguished by frequency of use, as regular users scored higher on psychological well-being and lower on psychopathology scales. Subjects with more psychological distress had lower scores for all scales of post-traumatic growth, but if they were regular hallucinogens users, they had higher scores for post-traumatic growth. When comparing the results between cultural contexts, heterogeneous results were obtained. There were more English-speaking regular users of hallucinogenic drugs. Further research should analyse the potential role of hallucinogens in large-scale catastrophes, with a special focus on post-traumatic growth.<\/jats:p>","DOI":"10.1038\/s41598-023-41199-x","type":"journal-article","created":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T10:02:24Z","timestamp":1694426544000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Longitudinal and transcultural assessment of the relationship between hallucinogens, well-being, and post-traumatic growth during the COVID-19 pandemic"],"prefix":"10.1038","volume":"13","author":[{"given":"Jos\u00e9 Carlos","family":"Bouso","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D\u00f3ra","family":"R\u00e9v\u00e9sz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gen\u00eds","family":"Ona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giordano N.","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliana M.","family":"Rocha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael G.","family":"dos Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaime E. C.","family":"Hallak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel \u00c1ngel","family":"Alc\u00e1zar-Corcoles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,11]]},"reference":[{"key":"41199_CR1","first-page":"3","volume":"93","author":"A de Vicente","year":"2021","unstructured":"de Vicente, A., Villamar\u00edn, S. & Berdullas, S. En Portada: La Nueva Pandemia Psicol\u00f3gica. Infocop. 93, 3\u20137 (2021).","journal-title":"Infocop."},{"key":"41199_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajp.2020.102066","volume":"52","author":"RP Rajkumar","year":"2020","unstructured":"Rajkumar, R. P. COVID-19 and mental health: A review of the existing literature. Asian J. Psychiatr. 52, 102066 (2020).","journal-title":"Asian J. Psychiatr."},{"key":"41199_CR3","unstructured":"OECD. Tackling the mental health impact of the COVID-19 crisis: An integrated, whole-of-society response. 2021. https:\/\/read.oecd-ilibrary.org\/view\/?ref=1094_1094455-bukuf1f0cm&title=Tackling-the-mental-health-impact-of-the-COVID-19-crisis-An-integrated-whole-of-society-response (accessed 13 June 2022)."},{"issue":"9","key":"41199_CR4","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1080\/17512433.2018.1511424","volume":"11","author":"RG Dos Santos","year":"2018","unstructured":"Dos Santos, R. G., Bouso, J. C., Alc\u00e1zar-C\u00f3rcoles, M. \u00c1. & Hallak, J. E. C. Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: A systematic review of systematic reviews. Expert Rev. Clin. Pharmacol. 11(9), 889\u2013902 (2018).","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"41199_CR5","doi-asserted-by":"publisher","first-page":"901","DOI":"10.2147\/RMHP.S300656","volume":"14","author":"RG Dos Santos","year":"2021","unstructured":"Dos Santos, R. G., Bouso, J. C., Rocha, J. M., Rossi, G. N. & Hallak, J. E. The use of classic hallucinogens\/psychedelics in a therapeutic context: Healthcare policy opportunities and challenges. Risk Manag. Healthc. Policy. 14, 901\u2013910 (2021).","journal-title":"Risk Manag. Healthc. Policy."},{"key":"41199_CR6","unstructured":"Efrati, I. Party Drug or Breakthrough Treatment? Israel Approves Compassionate Use of MDMA to Treat PTSD. Haaretz, 2019. https:\/\/www.haaretz.com\/science-and-health\/.premium-israel-s-health-ministry-approves-compassionate-use-of-mdma-to-treat-ptsd-1.6918710 (accessed 13 June 2022)."},{"issue":"3","key":"41199_CR7","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s11019-020-09958-z","volume":"23","author":"A Greif","year":"2020","unstructured":"Greif, A. & \u0160urkala, M. Compassionate use of psychedelics. Med. Health Care Philos. 23(3), 485\u2013496 (2020).","journal-title":"Med. Health Care Philos."},{"key":"41199_CR8","unstructured":"Jackson, P. Canada approves psilocybin for compassionate use in four patients. The Telegram. August 5, 2020. https:\/\/www.saltwire.com\/newfoundland-labrador\/news\/local\/canada-approves-psilocybin-for-compassionate-use-in-four-patients-481846\/ (accessed 13 June 2022)."},{"key":"41199_CR9","unstructured":"MAPS. Expanded Access Program: MDMA-Assisted Therapy for PTSD. 2019. https:\/\/maps.org\/research\/mdma\/ptsd\/expanded-access (accessed 13 June 2022)."},{"key":"41199_CR10","unstructured":"Landis-Hanley, J. Australian government backs psychedelic drug clinical trials to treat mental illness. The Guardian. March 18, 2021. https:\/\/www.theguardian.com\/australia-news\/2021\/mar\/18\/australian-government-backs-psychedelic-drug-clinical-trials-to-treat-mental-illness (accessed 13 June 2022)."},{"key":"41199_CR11","unstructured":"Martinez, M. Johns Hopkins receives first federal grant for psychedelic treatment research in 50 years. Hub. October 20, 2021. https:\/\/hub.jhu.edu\/2021\/10\/20\/first-nih-grant-for-psychedelics-in-50-years\/ (Accessed 13 June 2022)."},{"key":"41199_CR12","unstructured":"Daoud, E. Mind Medicine Australia urges psychedelic drugs for mental health treatment during COVID-19. 7News. April 15, 2020. https:\/\/7news.com.au\/lifestyle\/health-wellbeing\/mind-medicine-australia-urges-psychedelic-drugs-for-mental-health-treatment-during-covid-19-c-977749 (accessed 13 June 2022)."},{"issue":"2","key":"41199_CR13","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1017\/ipm.2020.94","volume":"38","author":"JR Kelly","year":"2021","unstructured":"Kelly, J. R. et al. Psychedelic science in post-COVID-19 psychiatry. Ir. J. Psychol. Med. 38(2), 93\u201398 (2021).","journal-title":"Ir. J. Psychol. Med."},{"issue":"4","key":"41199_CR14","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1590\/0101-60830000000130","volume":"44","author":"RG Dos Santos","year":"2017","unstructured":"Dos Santos, R. G., Bouso, J. C. & Hallak, J. E. C. Ayahuasca: What mental health professionals need to know. Arch. Clin. Psychiatry. 44(4), 103\u2013109 (2017).","journal-title":"Arch. Clin. Psychiatry."},{"issue":"1","key":"41199_CR15","doi-asserted-by":"publisher","first-page":"4075","DOI":"10.1038\/s41598-020-61169-x","volume":"10","author":"DF Jim\u00e9nez-Garrido","year":"2020","unstructured":"Jim\u00e9nez-Garrido, D. F. et al. Effects of ayahuasca on mental health and quality of life in na\u00efve users: A longitudinal and cross-sectional study combination. Sci. Rep. 10(1), 4075 (2020).","journal-title":"Sci. Rep."},{"issue":"4","key":"41199_CR16","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1007\/s00213-019-05446-2","volume":"237","author":"D Gonz\u00e1lez","year":"2020","unstructured":"Gonz\u00e1lez, D. et al. Therapeutic potential of ayahuasca in grief: A prospective, observational study. Psychopharmacology 237(4), 1171\u20131182 (2020).","journal-title":"Psychopharmacology"},{"issue":"3","key":"41199_CR17","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1177\/0030222817710879","volume":"79","author":"D Gonz\u00e1lez","year":"2019","unstructured":"Gonz\u00e1lez, D., Carvalho, M., Cantillo, J., Aixal\u00e1, M. & Farr\u00e9, M. Potential use of ayahuasca in grief therapy. Omega (Westport). 79(3), 260\u2013285 (2019).","journal-title":"Omega (Westport)."},{"issue":"2","key":"41199_CR18","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s00213-018-5085-3","volume":"236","author":"E Dom\u00ednguez-Clav\u00e9","year":"2019","unstructured":"Dom\u00ednguez-Clav\u00e9, E. et al. Ayahuasca improves emotion dysregulation in a community sample and in individuals with borderline-like traits. Psychopharmacology 236(2), 573\u2013580 (2019).","journal-title":"Psychopharmacology"},{"key":"41199_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jadr.2021.100098","volume":"4","author":"J Sarris","year":"2021","unstructured":"Sarris, J. et al. Ayahuasca use and reported effects on depression and anxiety symptoms: An international cross-sectional study of 11,912 consumers. J. Affect. Dis. Rep. 4, 100098. https:\/\/doi.org\/10.1016\/j.jadr.2021.100098 (2021).","journal-title":"J. Affect. Dis. Rep."},{"key":"41199_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.623979","volume":"12","author":"D Perkins","year":"2021","unstructured":"Perkins, D. et al. Influence of context and setting on the mental health and wellbeing outcomes of Ayahuasca drinkers: Results of a large international survey. Front. Pharmacol. 12, 623979 (2021).","journal-title":"Front. Pharmacol."},{"issue":"2","key":"41199_CR21","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1080\/02791072.2019.1567961","volume":"51","author":"G Ona","year":"2019","unstructured":"Ona, G. et al. Ayahuasca and public health: Health status, psychosocial well-being, lifestyle, and coping strategies in a large sample of ritual Ayahuasca users. J. Psychoactive Drugs. 51(2), 135\u2013145 (2019).","journal-title":"J. Psychoactive Drugs."},{"key":"41199_CR22","first-page":"1","volume":"55","author":"M Kohek","year":"2022","unstructured":"Kohek, M. et al. Ayahuasca and Public Health II: Health status in a large sample of Ayahuasca-ceremony participants in the Netherlands [published online ahead of print, 2022 May 28]. J. Psychoactive Drugs. 55, 1\u201312 (2022).","journal-title":"J. Psychoactive Drugs."},{"issue":"7","key":"41199_CR23","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1177\/0269881118771782","volume":"32","author":"MS Thiessen","year":"2018","unstructured":"Thiessen, M. S., Walsh, Z., Bird, B. M. & Lafrance, A. Psychedelic use and intimate partner violence: The role of emotion regulation. J. Psychopharmacol. 32(7), 749\u2013755 (2018).","journal-title":"J. Psychopharmacol."},{"issue":"7","key":"41199_CR24","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1177\/0269881116642538","volume":"30","author":"Z Walsh","year":"2016","unstructured":"Walsh, Z. et al. Hallucinogen use and intimate partner violence: Prospective evidence consistent with protective effects among men with histories of problematic substance use. J. Psychopharmacol. 30(7), 601\u2013607 (2016).","journal-title":"J. Psychopharmacol."},{"issue":"12","key":"41199_CR25","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1177\/0269881118798610","volume":"32","author":"E Argento","year":"2018","unstructured":"Argento, E., Braschel, M., Walsh, Z., Socias, M. E. & Shannon, K. The moderating effect of psychedelics on the prospective relationship between prescription opioid use and suicide risk among marginalized women. J. Psychopharmacol. 32(12), 1385\u20131391 (2018).","journal-title":"J. Psychopharmacol."},{"issue":"3","key":"41199_CR26","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1177\/0269881114565653","volume":"29","author":"PS Hendricks","year":"2015","unstructured":"Hendricks, P. S., Thorne, C. B., Clark, C. B., Coombs, D. W. & Johnson, M. W. Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. J. Psychopharmacol. 29(3), 280\u2013288 (2015).","journal-title":"J. Psychopharmacol."},{"issue":"3","key":"41199_CR27","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1177\/0269881114568039","volume":"29","author":"P\u00d8 Johansen","year":"2015","unstructured":"Johansen, P. \u00d8. & Krebs, T. S. Psychedelics not linked to mental health problems or suicidal behavior: A population study. J. Psychopharmacol. 29(3), 270\u2013279 (2015).","journal-title":"J. Psychopharmacol."},{"issue":"2","key":"41199_CR28","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s00213-020-05692-9","volume":"238","author":"RJ Zeifman","year":"2021","unstructured":"Zeifman, R. J. et al. Rapid and sustained decreases in suicidality following a single dose of ayahuasca among individuals with recurrent major depressive disorder: Results from an open-label trial. Psychopharmacology 238(2), 453\u2013459 (2021).","journal-title":"Psychopharmacology"},{"key":"41199_CR29","doi-asserted-by":"publisher","first-page":"782","DOI":"10.3389\/fpsyt.2020.00782","volume":"11","author":"RJ Zeifman","year":"2020","unstructured":"Zeifman, R. J. et al. Post-psychedelic reductions in experiential avoidance are associated with decreases in depression severity and suicidal ideation. Front. Psychiatry. 11, 782 (2020).","journal-title":"Front. Psychiatry."},{"key":"41199_CR30","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.3389\/fphar.2019.01325","volume":"10","author":"RJ Zeifman","year":"2019","unstructured":"Zeifman, R. J. et al. The impact of Ayahuasca on suicidality: Results from a randomized controlled trial. Front. Pharmacol. 10, 1325 (2019).","journal-title":"Front. Pharmacol."},{"issue":"8","key":"41199_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0042421","volume":"7","author":"JC Bouso","year":"2012","unstructured":"Bouso, J. C. et al. Personality, psychopathology, life attitudes and neuropsychological performance among ritual users of Ayahuasca: A longitudinal study. PLoS ONE 7(8), e42421 (2012).","journal-title":"PLoS ONE"},{"issue":"8","key":"41199_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0063972","volume":"8","author":"TS Krebs","year":"2013","unstructured":"Krebs, T. S. & Johansen, P. \u00d8. Psychedelics and mental health: A population study. PLoS ONE 8(8), e63972 (2013).","journal-title":"PLoS ONE"},{"issue":"4","key":"41199_CR33","first-page":"40","volume":"28","author":"V Bruno","year":"2022","unstructured":"Bruno, V., Wiazowski Spelta, L. E., Dur\u00e3o, A. C., Camarini, R. & Marcourakis, T. Psychedelics and mental health: An alternative strategy to treat mental impairments triggered or aggravated by COVID-19. Altern. Ther. Health Med. 28(4), 40\u201343 (2022).","journal-title":"Altern. Ther. Health Med."},{"issue":"2","key":"41199_CR34","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1556\/2054.2021.00172","volume":"5","author":"F Cavanna","year":"2021","unstructured":"Cavanna, F. et al. Lifetime use of psychedelics is associated with better mental health indicators during the COVID-19 pandemic. J. Psychedelic Stud. 5(2), 83\u201393 (2021).","journal-title":"J. Psychedelic Stud."},{"key":"41199_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.687546","volume":"12","author":"D R\u00e9v\u00e9sz","year":"2021","unstructured":"R\u00e9v\u00e9sz, D. et al. Cross-sectional associations between lifetime use of psychedelic drugs and psychometric measures during the COVID-19 confinement: A transcultural study. Front. Psychiatry. 12, 687546 (2021).","journal-title":"Front. Psychiatry."},{"key":"41199_CR36","first-page":"125","volume":"11","author":"KB Rocha","year":"2011","unstructured":"Rocha, K. B. et al. Propiedades psicom\u00e9tricas y valores normativos del General Health Questionnaire (GHQ-12) en poblaci\u00f3n general espa\u00f1ola. Int. J. Clin. Health Psychol. 11, 125\u2013139 (2011).","journal-title":"Int. J. Clin. Health Psychol."},{"key":"41199_CR37","unstructured":"Goldberg, D., Williams, P. A User\u2019s Guide to the General Health Questionnaire (NFER-Nelson, 1988)."},{"key":"41199_CR38","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1590\/S0102-311X2012000200016","volume":"28","author":"VV Gouveia","year":"2003","unstructured":"Gouveia, V. V. et al. Question\u00e1rio de Sa\u00fade Geral (QSG-12): o efeito de itens negativos em sua estrutura fatorial. Cad Sa\u00fade P\u00fablica. 28, 375\u2013384 (2003).","journal-title":"Cad Sa\u00fade P\u00fablica."},{"key":"41199_CR39","doi-asserted-by":"crossref","unstructured":"Derogatis, L. R. Brief Symptom Inventory (Clinical Psychometric Research, 1975).","DOI":"10.1037\/t48311-000"},{"key":"41199_CR40","unstructured":"Laloni, D. T. Escala de Avalia\u00e7\u00e3o de Sintomas-90-R. SCL-90-R Adapta\u00e7\u00e3o Previs\u00e3o e Validade. Campinas (Disserta\u00e7\u00e3o de mestrado) Instituito de Psicologia e Fonoaudiologia\u2014programa de P\u00f3s-Gradua\u00e7\u00e3o\u2014Psicologia como Profiss\u00e3o e Ci\u00eancia, Pontif\u00edcia Universidade Cat\u00f3lica de Campinas (2001)."},{"key":"41199_CR41","unstructured":"Gonz\u00e1lez de Rivera, J. L., Derogatis, L. R., De las Cuevas, C., Gracia Marco, R., Rodr\u00edguez Pulido, F., Henry Ben\u00edtez, M., Monterrey, A. L. The Spanish Version of the SCL-90-R. Normative Data in the General Population (Clinical Psychometric Research, 1989)."},{"issue":"9","key":"41199_CR42","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1176\/appi.ajp.158.9.1480","volume":"158","author":"A Brunet","year":"2001","unstructured":"Brunet, A. et al. The Peritraumatic Distress Inventory: A proposed measure of PTSD criterion A2. Am. J. Psychiatry. 158(9), 1480\u20131485 (2001).","journal-title":"Am. J. Psychiatry."},{"issue":"3","key":"41199_CR43","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/jts.2490090305","volume":"9","author":"RG Tedeschi","year":"1996","unstructured":"Tedeschi, R. G. & Calhoun, L. G. The Posttraumatic Growth Inventory: Measuring the positive legacy of trauma. J. Trauma Stress. 9(3), 455\u2013471 (1996).","journal-title":"J. Trauma Stress."},{"key":"41199_CR44","unstructured":"Resende, C., Sendas, S., Maia, A. Estudo das Caracter\u00edsticas Psicom\u00e9tricas do Posttraumatic Growth Inventory\u2014PTGI\u2014(Invent\u00e1rio de Crescimento P\u00f3s-Traum\u00e1tico) para a Popula\u00e7\u00e3o Portuguesa. In Actas da XIII Confer\u00eancia Internacional de Avalia\u00e7\u00e3o Psicol\u00f3gica: Formas e Contextos (2008)."},{"issue":"148","key":"41199_CR45","first-page":"229","volume":"33","author":"G Costa-Requena","year":"2007","unstructured":"Costa-Requena, G. & Gil, F. L. Crecimiento postraum\u00e1tico en pacientes oncol\u00f3gicos. Analisis Modificaci\u00f3n Conducta. 33(148), 229\u2013250 (2007).","journal-title":"Analisis Modificaci\u00f3n Conducta."},{"issue":"8","key":"41199_CR46","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1023\/B:EJEP.0000036572.00663.f2","volume":"19","author":"JW Twisk","year":"2004","unstructured":"Twisk, J. W. Longitudinal data analysis. A comparison between generalized estimating equations and random coefficient analysis. Eur. J. Epidemiol. 19(8), 769\u2013776 (2004).","journal-title":"Eur. J. Epidemiol."},{"issue":"7","key":"41199_CR47","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1080\/10826084.2022.2063896","volume":"57","author":"D Daldegan-Bueno","year":"2022","unstructured":"Daldegan-Bueno, D., R\u00e9v\u00e9sz, D., Morais, P. R., Barbosa, P. C. R. & Maia, L. O. Psychosocial and drug use assessment of regular vs non-regular Ayahuasca users in a Brazilian sample: A web-based survey. Subst. Use Misuse. 57(7), 1072\u20131081 (2022).","journal-title":"Subst. Use Misuse."},{"key":"41199_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.831092","volume":"13","author":"CL Raison","year":"2022","unstructured":"Raison, C. L., Jain, R., Penn, A. D., Cole, S. P. & Jain, S. Effects of naturalistic psychedelic use on depression, anxiety, and well-being: Associations with patterns of use, reported harms, and transformative mental states. Front. Psychiatry. 13, 831092 (2022).","journal-title":"Front. Psychiatry."},{"issue":"2","key":"41199_CR49","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1021\/acsptsci.1c00024","volume":"4","author":"RJ Zeifman","year":"2021","unstructured":"Zeifman, R. J. et al. On the relationship between classic psychedelics and suicidality: A systematic review. ACS Pharmacol. Transl. Sci. 4(2), 436\u2013451 (2021).","journal-title":"ACS Pharmacol. Transl. Sci."},{"issue":"1","key":"41199_CR50","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1177\/0269881117735685","volume":"32","author":"PS Hendricks","year":"2018","unstructured":"Hendricks, P. S. et al. The relationships of classic psychedelic use with criminal behavior in the United States adult population. J. Psychopharmacol. 32(1), 37\u201348 (2018).","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"41199_CR51","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1177\/02698811211058933","volume":"36","author":"GM Jones","year":"2022","unstructured":"Jones, G. M. & Nock, M. K. Psilocybin use is associated with lowered odds of crime arrests in US adults: A replication and extension. J. Psychopharmacol. 36(1), 66\u201373 (2022).","journal-title":"J. Psychopharmacol."},{"issue":"16","key":"41199_CR52","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1017\/S003329172000389X","volume":"50","author":"SB Goldberg","year":"2020","unstructured":"Goldberg, S. B. et al. Post-acute psychological effects of classical serotonergic psychedelics: A systematic review and meta-analysis. Psychol. Med. 50(16), 2655\u20132666 (2020).","journal-title":"Psychol. Med."},{"issue":"4","key":"41199_CR53","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1080\/02791072.2020.1769878","volume":"52","author":"JB Luoma","year":"2020","unstructured":"Luoma, J. B., Chwyl, C., Bathje, G. J., Davis, A. K. & Lancelotta, R. A meta-analysis of placebo-controlled trials of psychedelic-assisted therapy. J. Psychoactive Drugs. 52(4), 289\u2013299 (2020).","journal-title":"J. Psychoactive Drugs."},{"issue":"4","key":"41199_CR54","doi-asserted-by":"publisher","first-page":"938","DOI":"10.3390\/jcm11040938","volume":"11","author":"CL Yu","year":"2022","unstructured":"Yu, C. L. et al. Trajectory of antidepressant effects after single- or two-dose administration of psilocybin: A systematic review and multivariate meta-analysis. J. Clin. Med. 11(4), 938 (2022).","journal-title":"J. Clin. Med."},{"issue":"1","key":"41199_CR55","doi-asserted-by":"publisher","DOI":"10.1002\/hup.2807","volume":"37","author":"E Dom\u00ednguez-Clav\u00e9","year":"2022","unstructured":"Dom\u00ednguez-Clav\u00e9, E. et al. Ayahuasca may help to improve self-compassion and self-criticism capacities. Hum. Psychopharmacol. 37(1), e2807 (2022).","journal-title":"Hum. Psychopharmacol."},{"key":"41199_CR56","doi-asserted-by":"crossref","first-page":"204512532098663","DOI":"10.1177\/2045125320986634","volume":"11","author":"DM O'Shaughnessy","year":"2021","unstructured":"O\u2019Shaughnessy, D. M., Berlowitz, I., Rodd, R., Sarnyai, Z. & Quirk, F. Within-treatment changes in a novel addiction treatment program using traditional Amazonian medicine. Ther. Adv. Psychopharmacol. 11, 2045125320986634 (2021).","journal-title":"Ther. Adv. Psychopharmacol."},{"issue":"1","key":"41199_CR57","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/dar.13348","volume":"41","author":"D Perkins","year":"2022","unstructured":"Perkins, D. et al. Associations between ayahuasca consumption in naturalistic settings and current alcohol and drug use: Results of a large international cross-sectional survey. Drug Alcohol Rev. 41(1), 265\u2013274 (2022).","journal-title":"Drug Alcohol Rev."},{"key":"41199_CR58","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.comppsych.2016.09.003","volume":"71","author":"PC Barbosa","year":"2016","unstructured":"Barbosa, P. C. et al. Psychological and neuropsychological assessment of regular hoasca users. Compr. Psychiatry. 71, 95\u2013105 (2016).","journal-title":"Compr. Psychiatry."},{"issue":"3","key":"41199_CR59","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s00213-013-3167-9","volume":"230","author":"JC Bouso","year":"2013","unstructured":"Bouso, J. C., F\u00e1bregas, J. M., Antonijoan, R. M., Rodr\u00edguez-Fornells, A. & Riba, J. Acute effects of ayahuasca on neuropsychological performance: Differences in executive function between experienced and occasional users. Psychopharmacology 230(3), 415\u2013424 (2013).","journal-title":"Psychopharmacology"},{"issue":"2","key":"41199_CR60","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1080\/02791072.2005.10399791","volume":"37","author":"E Doering-Silveira","year":"2005","unstructured":"Doering-Silveira, E. et al. Ayahuasca in adolescence: A neuropsychological assessment. J. Psychoactive Drugs. 37(2), 123\u2013128 (2005).","journal-title":"J. Psychoactive Drugs."},{"key":"41199_CR61","volume-title":"Neuropsychological Effect on Long-Term Ayahuasca Use","author":"TD Tucker","year":"2018","unstructured":"Tucker, T. D. Neuropsychological Effect on Long-Term Ayahuasca Use (Georgia State University, 2018)."},{"issue":"1","key":"41199_CR62","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/psychoactives1010003","volume":"1","author":"G Ona","year":"2022","unstructured":"Ona, G. et al. Tripping to cope: Coping strategies and use of hallucinogens during the COVID-19 pandemic in three cultural contexts. Psychoactives 1(1), 16\u201330. https:\/\/doi.org\/10.3390\/psychoactives1010003 (2022).","journal-title":"Psychoactives"},{"issue":"4","key":"41199_CR63","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1002\/jcph.1995","volume":"62","author":"KW Smith","year":"2022","unstructured":"Smith, K. W., Sicignano, D. J., Hernandez, A. V. & White, C. M. MDMA-assisted psychotherapy for treatment of posttraumatic stress disorder: A systematic review with meta-analysis. J. Clin. Pharmacol. 62(4), 463\u2013471 (2022).","journal-title":"J. Clin. Pharmacol."},{"key":"41199_CR64","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.702838","volume":"12","author":"AC Wagner","year":"2021","unstructured":"Wagner, A. C., Liebman, R. E., Mithoefer, A. T., Mithoefer, M. C. & Monson, C. M. Relational and growth outcomes following couples therapy with MDMA for PTSD. Front. Psychiatry. 12, 702838 (2021).","journal-title":"Front. Psychiatry."},{"issue":"2","key":"41199_CR65","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1002\/jts.22479","volume":"33","author":"I Gorman","year":"2020","unstructured":"Gorman, I. et al. Posttraumatic growth after MDMA-assisted psychotherapy for posttraumatic stress disorder. J. Trauma Stress. 33(2), 161\u2013170 (2020).","journal-title":"J. Trauma Stress."},{"key":"41199_CR66","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/7854_2017_474","volume":"36","author":"FS Barrett","year":"2018","unstructured":"Barrett, F. S. & Griffiths, R. R. Classic hallucinogens and mystical experiences: Phenomenology and neural correlates. Curr. Top. Behav. Neurosci. 36, 393\u2013430 (2018).","journal-title":"Curr. Top. Behav. Neurosci."},{"issue":"4","key":"41199_CR67","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1080\/02791072.2020.1767321","volume":"52","author":"S Kangaslampi","year":"2020","unstructured":"Kangaslampi, S., Hausen, A. & Rauteenmaa, T. Mystical experiences in retrospective reports of first times using a psychedelic in Finland. J. Psychoactive Drugs. 52(4), 309\u2013318 (2020).","journal-title":"J. Psychoactive Drugs."},{"key":"41199_CR68","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3389\/fnhum.2016.00269","volume":"10","author":"MM Nour","year":"2016","unstructured":"Nour, M. M., Evans, L., Nutt, D. & Carhart-Harris, R. L. Ego-dissolution and psychedelics: Validation of the ego-dissolution inventory (EDI). Front. Hum. Neurosci. 10, 269 (2016).","journal-title":"Front. Hum. Neurosci."},{"issue":"1","key":"41199_CR69","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1177\/02698811211066709","volume":"36","author":"JM Peill","year":"2022","unstructured":"Peill, J. M. et al. Validation of the Psychological Insight Scale: A new scale to assess psychological insight following a psychedelic experience. J. Psychopharmacol. 36(1), 31\u201345 (2022).","journal-title":"J. Psychopharmacol."},{"issue":"12","key":"41199_CR70","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1177\/0269881116662634","volume":"30","author":"TM Carbonaro","year":"2016","unstructured":"Carbonaro, T. M. et al. Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. J. Psychopharmacol. 30(12), 1268\u20131278 (2016).","journal-title":"J. Psychopharmacol."},{"issue":"2","key":"41199_CR71","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1097\/JCP.0000000000001343","volume":"41","author":"M G\u00f3mez-Sousa","year":"2021","unstructured":"G\u00f3mez-Sousa, M. et al. Acute psychological adverse reactions in first-time ritual Ayahuasca users: A prospective case series. J. Clin. Psychopharmacol. 41(2), 163\u2013171 (2021).","journal-title":"J. Clin. Psychopharmacol."},{"issue":"4","key":"41199_CR72","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1111\/1556-4029.13982","volume":"64","author":"E Honyiglo","year":"2019","unstructured":"Honyiglo, E. et al. Unpredictable behavior under the influence of \u201cmagic mushrooms\u201d: A case report and review of the literature. J. Forensic Sci. 64(4), 1266\u20131270 (2019).","journal-title":"J. Forensic Sci."},{"issue":"1","key":"41199_CR73","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1556\/2054.2018.001","volume":"2","author":"G Ona","year":"2018","unstructured":"Ona, G. Inside bad trips: Exploring extra-pharmacological factors. J. Psychedelic Stud. 2(1), 53\u201360 (2018).","journal-title":"J. Psychedelic Stud."},{"issue":"5\u20136","key":"41199_CR74","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1097\/FBP.0000000000000060","volume":"25","author":"AC Parrott","year":"2014","unstructured":"Parrott, A. C. et al. MDMA, cortisol, and heightened stress in recreational ecstasy users. Behav. Pharmacol. 25(5\u20136), 458\u2013472 (2014).","journal-title":"Behav. Pharmacol."},{"issue":"4","key":"41199_CR75","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1590\/1516-4446-2020-0913","volume":"43","author":"\u00cd Durante","year":"2021","unstructured":"Durante, \u00cd., Dos Santos, R. G., Bouso, J. C. & Hallak, J. E. Risk assessment of ayahuasca use in a religious context: Self-reported risk factors and adverse effects. Braz. J. Psychiatry. 43(4), 362\u2013369 (2021).","journal-title":"Braz. J. Psychiatry."},{"key":"41199_CR76","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.neubiorev.2018.02.004","volume":"87","author":"JC Bouso","year":"2018","unstructured":"Bouso, J. C., Dos Santos, R. G., Alc\u00e1zar-C\u00f3rcoles, M. \u00c1. & Hallak, J. E. C. Serotonergic psychedelics and personality: A systematic review of contemporary research. Neurosci. Biobehav. Rev. 87, 118\u2013132 (2018).","journal-title":"Neurosci. Biobehav. Rev."},{"key":"41199_CR77","doi-asserted-by":"crossref","unstructured":"Hermle, L., Kraehenmann, R. Experimental psychosis research and schizophrenia\u2014Similarities and dissimilarities in psychopathology In Behavioral Neurobiology of Psychedelic Drugs. Current Topics in Behavioral Neurosciences, vol 36 (eds. Halberstadt, A. L., Vollenweider, F., Nichols, D.) 313\u2013332 (Springer, 2018).","DOI":"10.1007\/7854_2016_460"},{"key":"41199_CR78","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1007\/s11013-022-09814-0","volume":"47","author":"JC Bouso","year":"2022","unstructured":"Bouso, J. C. et al. Hallucinations and hallucinogens: Psychopathology or wisdom?. Cult. Med. Psychiatry. 47, 576\u2013604 (2022).","journal-title":"Cult. Med. Psychiatry."},{"issue":"5","key":"41199_CR79","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000028625","volume":"101","author":"J G\u00f3mez-Salgado","year":"2022","unstructured":"G\u00f3mez-Salgado, J. et al. COVID-19 information received by the Peruvian population, during the first phase of the pandemic, and its association with developing psychological distress: Information about COVID-19 and distress in Peru. Medicine (Baltimore) 101(5), e28625 (2022).","journal-title":"Medicine (Baltimore)"},{"issue":"24","key":"41199_CR80","doi-asserted-by":"publisher","first-page":"13198","DOI":"10.3390\/ijerph182413198","volume":"18","author":"J Hwang","year":"2021","unstructured":"Hwang, J., Borah, P., Shah, D. & Brauer, M. The relationship among COVID-19 information seeking, news media use, and emotional distress at the onset of the pandemic. Int. J. Environ. Res. Public Health. 18(24), 13198 (2021).","journal-title":"Int. J. Environ. Res. Public Health."},{"key":"41199_CR81","doi-asserted-by":"publisher","DOI":"10.3389\/fnbeh.2022.901425","volume":"16","author":"MLP de Meiroz Grilo","year":"2022","unstructured":"de Meiroz Grilo, M. L. P. et al. Prophylactic action of ayahuasca in a non-human primate model of depressive-like behavior. Front. Behav. Neurosci. 16, 901425 (2022).","journal-title":"Front. Behav. Neurosci."},{"key":"41199_CR82","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.neuropharm.2018.05.012","volume":"142","author":"MW Johnson","year":"2018","unstructured":"Johnson, M. W., Griffiths, R. R., Hendricks, P. S. & Henningfield, J. E. The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. Neuropharmacology 142, 143\u2013166 (2018).","journal-title":"Neuropharmacology"},{"key":"41199_CR83","doi-asserted-by":"crossref","unstructured":"Scientific American (Eds.). End the ban on psychoactive drug research. Sci. Am. 310(2), 10 (2014).","DOI":"10.1038\/scientificamerican0214-10"},{"key":"41199_CR84","unstructured":"GENCAT (Generalitat de Catalunya). Cap a millors pr\u00e0ctiques en l\u2019\u00fas de l\u2019ayahuasca. 2019. https:\/\/drogues.gencat.cat\/ca\/detalls\/Noticia\/Cap-a-millors-practiques-en-lus-de-layahuasca (accessed 13 June 2022)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-41199-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-41199-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-41199-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T07:05:28Z","timestamp":1700377528000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-41199-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,11]]},"references-count":84,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["41199"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-41199-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,11]]},"assertion":[{"value":"16 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14052"}}